TOPRAZOLE 20/MG EC TAB 15/TAB

Indications

Approved Uses

Erosive esophagitis associated with GERD (healing) and maintenance of healing; pathological hypersecretory conditions including Zollinger-Ellison syndrome.

Off-Label Uses

Off-label (varies by guideline/institution): stress ulcer prophylaxis in critically ill patients (often IV/oral depending on setting), laryngopharyngeal reflux, functional dyspepsia.

Dosage & Administration

Dosing by Condition

Erosive esophagitis (healing): 40 mg orally once daily for up to 8 weeks (some patients may require an additional 8 weeks). Maintenance of healed erosive esophagitis: 20-40 mg once daily. Pathological hypersecretory conditions (e.g., Zollinger-Ellison): start 40 mg twice daily and titrate to clinical response (doses up to 240 mg/day have been used).

Initial Dose

20mg once daily for GERD; 40mg once daily for erosive esophagitis or peptic ulcer

Maintenance Dose

20mg to 40mg once daily for maintenance of healing of erosive esophagitis.

Maximum Dose

240mg per day (Zollinger-Ellison syndrome); 80mg per day for standard indications

Children's Dosage

Approved for children 5 years and older. 15 to <40 kg: 20mg once daily for up to 8 weeks. ≥40 kg: 40mg once daily for up to 8 weeks.

Dose Adjustment Notes

No dose adjustment is required in renal impairment. In hepatic impairment, use caution; some labels recommend not exceeding 20 mg/day in severe hepatic impairment and/or monitoring liver enzymes. No routine dose reduction is recommended solely for CYP2C19 poor metabolizers.

How to Take

Swallow the enteric‑coated tablet whole with water; do not crush, chew, or split. Preferably take before a meal (commonly 30-60 minutes before breakfast for once‑daily dosing).

Safety & Warnings

Contraindications

Hypersensitivity to pantoprazole/other PPIs (substituted benzimidazoles) or excipients; concomitant use with rilpivirine-containing products.

Warnings & Precautions

Key precautions: may mask gastric malignancy-evaluate alarm features; risk of C. difficile diarrhea; hypomagnesemia (consider monitoring if prolonged therapy or with digoxin/diuretics); osteoporosis-related fractures with long-term/high-dose use; vitamin B12 deficiency with long-term use; fundic gland polyps with long-term use; acute interstitial nephritis; consider lupus (cutaneous/systemic) if suggestive symptoms occur.

Age Restriction

Pediatric use depends on indication: for GERD/erosive esophagitis, pantoprazole is generally approved for children ≥5 years; not established/approved for <5 years.

Drug Interactions

Interaction Severity

MAJOR/Contraindicated or avoid: rilpivirine; avoid with atazanavir or nelfinavir (reduced absorption with increased gastric pH). MODERATE: warfarin (monitor INR), high‑dose methotrexate (consider holding PPI/monitor), drugs needing acidic pH for absorption such as ketoconazole/itraconazole (reduced effect), and iron salts (reduced absorption). MINOR: digoxin (possible increased levels, monitor if high risk); clopidogrel interaction is less clinically significant with pantoprazole than with omeprazole/esomeprazole.

Food Interaction

May be taken with or without food, but taking it before a meal (about 30-60 minutes prior) is preferred for best acid suppression.

Special Populations

Pregnancy

Not assigned a pregnancy category (Category C prior to 2015; now uses descriptive text: based on animal data, may cause fetal harm.

Children

Approved for children 5 years and older. 15 to <40 kg: 20mg once daily for up to 8 weeks. ≥40 kg: 40mg once daily for up to 8 weeks.

Storage & Patient Advice

Stopping the Medicine

Can be stopped when clinically appropriate; after prolonged use, consider tapering/step-down to reduce rebound acid hypersecretion.

Patient Counseling

Swallow the enteric‑coated tablet whole (do not crush/chew/split); take once daily preferably 30-60 minutes before a meal for best effect. Use for the prescribed duration; if a dose is missed, take it when remembered unless near the next dose (do not double). Seek medical advice for severe/persistent diarrhea (possible C. difficile), signs of allergy, or symptoms of hypomagnesemia (e.g., muscle cramps/weakness, palpitations/seizures) especially with prolonged use; long‑term therapy may warrant monitoring magnesium and vitamin B12 and may increase fracture risk-ensure adequate calcium/vitamin D if at risk. Check for interactions: may reduce absorption of drugs needing acidic pH (e.g., ketoconazole/itraconazole/erlotinib) and is generally avoided with atazanavir/nelfinavir; use caution/monitoring with warfarin and high‑dose methotrexate.

Monitoring Requirements

For long-term therapy: consider magnesium (especially if on diuretics/digoxin), vitamin B12 with prolonged use, and fracture risk/bone health in at-risk patients; monitor INR if used with warfarin; consider liver enzymes in significant hepatic disease.

Pharmacology

Mechanism of Action

Pantoprazole is a proton pump inhibitor that irreversibly inhibits the gastric parietal cell H+/K+-ATPase (proton pump), blocking the final step of acid secretion.

Onset of Action

Initial acid suppression begins within a few hours (about 2-3 hours), but maximal clinical effect typically requires 2-4 days of daily dosing.

Duration of Effect

Approximately 24 hours per dose (acid suppression persists about a day, though maximal effect requires several days of dosing).

Half-Life

Approximately 1 hour (about 1-1.5 hours in healthy adults).

Bioavailability

Approximately 77%.

Metabolism

Extensively hepatic metabolism, primarily via CYP2C19 with a minor contribution from CYP3A4 (with first-pass metabolism).

Excretion

Approximately 71% excreted in urine (mainly as metabolites) and ~18% in feces/bile.

Protein Binding

Approximately 98%, primarily to albumin.

Product Information

Available Dosage Forms

Enteric‑coated (delayed‑release) oral tablet (this product: 20 mg EC tablet). Other pantoprazole dosage forms that may exist in the market include delayed‑release granules/oral suspension and IV injection, but they are not this product.

Composition per Dose

Each enteric-coated tablet: 20mg pantoprazole as pantoprazole sodium sesquihydrate.

Generic Availability

Yes

OTC Alternatives

OTC alternatives for mild/intermittent reflux symptoms (market-dependent): antacids (e.g., aluminum/magnesium hydroxide, calcium carbonate) and H2 blockers (e.g., famotidine). OTC omeprazole is available in some countries, but this specific product (pantoprazole 20 mg EC) is prescription-only per SFDA.

Gi Condition

Acid Reflux/GERD, Ulcer

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.